[2017年糖尿病学新闻]
[News in diabetology 2017].
作者信息
Jornayvaz François R
机构信息
Unité de diabétologie, Service d'endocrinologie, diabétologie, hypertension et nutrition, HUG, 1211 Genève 14.
出版信息
Rev Med Suisse. 2018 Jan 10;14(588-589):30-33.
PMID:29337445
Abstract
The field of diabetes is constantly evolving, with numerous new molecules reaching the market for the treatment of type 2 diabetes. Paradoxically, this drug jungle is difficult for the primary care physician and can lead to therapeutic inertia. The aim of this article is to discuss new molecules and new cardiovascular outcome studies that lead to changes in guidelines pertinent to the pharmacological treatment of type 2 diabetes.
摘要
糖尿病领域不断发展，众多新分子进入市场用于治疗2型糖尿病。矛盾的是，这片药物丛林对初级保健医生来说颇具难度，可能导致治疗惰性。本文旨在探讨导致2型糖尿病药物治疗相关指南发生变化的新分子和新的心血管结局研究。
Zotero 插件